IL-CULLIGAN
Culligan International (“Culligan”), the innovative brand in consumer-focused, sustainable water solutions and services, and Waterlogic Group Holdings (“Waterlogic”), a global designer, manufacturer, distributor and service provider of purified drinking water dispensers, announced today the completion of their transaction to combine, creating a leader in clean and sustainable drinking water solutions and services. Headquartered in Rosemont, Illinois, the combined company operates under the Culligan name.
With over 11,000 employees operating directly in 30 countries, Culligan generates combined annual revenues of about $2.4 billion and is well-positioned to expand in the fast-growing $35 billion global consumer water market. The combination diversifies the company’s product range and increases its global reach, including an expansive dealer network in more than 70 countries. It brings additional scale and expertise to drive innovation in the development of new household and commercial water filtration, purification and treatment solutions, expanding those to both existing and new markets, and it bolsters distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific.
“Our two organizations make a powerful combined team as one Culligan, aligned on values and committed to a clear purpose to change people’s lives and to improve the environment,” said Scott Clawson, President and CEO of Culligan International. “Culligan is a leading global consumer water solutions and services provider whose mission is to deliver clean, safe and soft water to improve consumers’ health and wellness and reduce single-use plastics. Serving over 100 million people globally, our solutions save more than 40 billion plastic bottles annually.”
“Our deep, mutual belief that we have the ability and responsibility to contribute positively to the Earth guides our decisions and is engrained in our operations,” said Jeremy Ben-David, founder and former Group CEO of Waterlogic who now serves Culligan as CEO of the Europe, Middle East and Africa region, and a member of the Executive Leadership of Culligan Global. “We take to heart the United Nations Sustainable Development Goals, and today we are aligned to make an even more positive impact in all we do.”
The combined company is majority owned by funds affiliated with BDT Capital Partners, LLC (“BDT”) and by the firm’s co-investors. In 2021, funds managed by BDT, an affiliate of BDT & Company, LLC, a merchant bank that works with family- and founder-led businesses to pursue their strategic and financial objectives, acquired Culligan alongside a group of strategic family business owners and investors within the firm’s global network. Waterlogic was acquired in January 2015 by funds managed by Castik Capital, a European private equity investor, which alongside former Waterlogic management team members and other shareholders, has a meaningful minority ownership position in Culligan.
Terms of the transaction were not disclosed.
About Culligan International
Founded in 1936 and headquartered in Rosemont, Illinois, Culligan International makes a real difference to people’s lives by providing clean, safe, great-tasting water to more than 100 million consumers globally. With over 11,000 employees in 30 countries, we generate combined annual revenues of about $2.4 billion and are well-positioned to expand in the $35 billion global consumer water market. Culligan is one of the world’s most-recognized and trusted names in water, a reputation built through an 85-year legacy of trust, innovation, service and quality. The Culligan master brand covers a family of iconic brands and innovative technologies that include Quench, Blupura, Zip Water, Purezza Premium Water and Firewall® UVC purification. Our combination with Waterlogic diversifies our product range and increases our global reach, including through an expansive dealer network in over 70 countries. It helps bring a breadth of household, commercial and retail solutions to new markets and distribution channels across the Americas, Europe, the Middle East, Africa and Asia Pacific. As a purpose-led business, we strive to reduce the environmental impact across the supply chain, and we save more than 40 billion plastic bottles annually through our sustainable water filtration, purification and treatment solutions. For more information visit: www.corporate.culligan.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006416/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom